CY2567B1 - Treatment of normotensive glaucoma with angiotensin II antagonists - Google Patents

Treatment of normotensive glaucoma with angiotensin II antagonists

Info

Publication number
CY2567B1
CY2567B1 CY0600030A CY0600030A CY2567B1 CY 2567 B1 CY2567 B1 CY 2567B1 CY 0600030 A CY0600030 A CY 0600030A CY 0600030 A CY0600030 A CY 0600030A CY 2567 B1 CY2567 B1 CY 2567B1
Authority
CY
Cyprus
Prior art keywords
pct
treatment
angiotensin
antagonists
sec
Prior art date
Application number
CY0600030A
Other languages
English (en)
Inventor
Alica Huxley
Georg Mathis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2567B1 publication Critical patent/CY2567B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
CY0600030A 1994-02-08 2006-11-02 Treatment of normotensive glaucoma with angiotensin II antagonists CY2567B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94810071 1994-02-08

Publications (1)

Publication Number Publication Date
CY2567B1 true CY2567B1 (en) 2008-07-02

Family

ID=8218203

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0600030A CY2567B1 (en) 1994-02-08 2006-11-02 Treatment of normotensive glaucoma with angiotensin II antagonists

Country Status (17)

Country Link
US (1) US5889020A (es)
EP (1) EP0743852B1 (es)
JP (1) JPH09508641A (es)
CN (1) CN1140409A (es)
AT (1) ATE300287T1 (es)
AU (1) AU1423795A (es)
CA (1) CA2181461A1 (es)
CY (1) CY2567B1 (es)
DE (1) DE69534339T2 (es)
DK (1) DK0743852T3 (es)
ES (1) ES2243933T3 (es)
FI (1) FI963083A (es)
IL (1) IL112520A0 (es)
MX (1) MX9603259A (es)
NO (1) NO963064D0 (es)
WO (1) WO1995021609A1 (es)
ZA (1) ZA95958B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
HUT74734A (en) * 1994-03-16 1997-02-28 Sankyo Co Use of biphenyl methyl imidazole derivatives for producing pharmaceutical compositions having ocular tension derpessant activity
JPH10167961A (ja) * 1996-12-11 1998-06-23 Santen Pharmaceut Co Ltd 緑内障治療剤
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
NZ509260A (en) * 1998-07-10 2003-09-26 Novartis Ag Pharmaceutical composition containing valsartan and a calcium channel blocker
MXPA01010923A (es) * 1999-04-28 2002-06-21 Takeda Chemical Industries Ltd Composicion farmaceutica para prevenir, tratar o inhibir la evolucion de la retinopatia simple y la retinopatia preproliferativa.
ES2242619T3 (es) * 1999-06-11 2005-11-16 Sankyo Company, Limited Composicion para disminuir la tension ocular para la administracion topica.
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
WO2001030388A1 (fr) * 1999-10-25 2001-05-03 Senju Pharmaceutical Co., Ltd. Agents permettant de soulager la tension d'un muscle ciliaire
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
US6833381B2 (en) 2000-02-18 2004-12-21 Takeda Chemical Industries, Ltd. TNF-α inhibitors
AU2002218527A1 (en) * 2000-12-05 2002-06-18 Sankyo Company Limited Ocular tension-lowering compositions for topical administration
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
ES2535291T3 (es) * 2003-04-15 2015-05-08 Daiichi Sankyo Company, Limited Medoxomilo de olmesartán para prevención o tratamiento de enfermedades oculares angiogénicas
PL1750862T3 (pl) * 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
US20060160871A1 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
PL1872783T3 (pl) * 2005-04-21 2012-05-31 Santen Pharmaceutical Co Ltd Środek leczniczy w schorzeniach rogówkowo-spojówkowych
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
DK2376101T3 (en) * 2008-12-29 2016-01-18 Trevena Inc BETA-arrestin effectors AND COMPOSITIONS AND METHODS FOR USE THEREOF
RU2443416C2 (ru) * 2010-05-17 2012-02-27 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Капли глазные
EP3102223A4 (en) 2014-02-07 2017-11-29 Trevena, Inc. Crystalline and amorphous forms of a beta-arrestin effector
EP3145524A4 (en) 2014-05-19 2018-03-14 Trevena, Inc. Synthesis of beta-arrestin effectors
CN105188250A (zh) * 2015-09-09 2015-12-23 上海联影医疗科技有限公司 靶组件以及具有该靶组件的直线加速器
CN105244434B (zh) * 2015-10-13 2017-10-10 北京科技大学 一种C掺杂ZnO热电材料的制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430709A3 (en) * 1989-12-01 1992-02-12 Glaxo Group Limited Benzthiophen derivatives
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma

Also Published As

Publication number Publication date
CN1140409A (zh) 1997-01-15
ATE300287T1 (de) 2005-08-15
NO963064L (no) 1996-07-23
ES2243933T3 (es) 2005-12-01
WO1995021609A1 (en) 1995-08-17
EP0743852A1 (en) 1996-11-27
IL112520A0 (en) 1995-05-26
US5889020A (en) 1999-03-30
AU1423795A (en) 1995-08-29
MX9603259A (es) 1997-03-29
FI963083A0 (fi) 1996-08-05
EP0743852B1 (en) 2005-07-27
DE69534339D1 (de) 2005-09-01
FI963083A (fi) 1996-08-07
DK0743852T3 (da) 2005-10-17
DE69534339T2 (de) 2006-05-24
ZA95958B (en) 1995-08-08
CA2181461A1 (en) 1995-08-17
NO963064D0 (no) 1996-07-23
JPH09508641A (ja) 1997-09-02

Similar Documents

Publication Publication Date Title
CY2567B1 (en) Treatment of normotensive glaucoma with angiotensin II antagonists
MY117251A (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
IL142768A0 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
EP2298298A3 (en) Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
WO2001072291A3 (en) Treatment of movement disorders with metabotropic glutamate receptor antagonist
WO1999024051A3 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
ES2185660T3 (es) Nuevo uso de dexmedetomidina.
AU1667500A (en) N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
CA2338066A1 (en) Treatment of dyskinesia
TW324662B (en) Benzamide-containing pharmaceutical composition
AU2001263130A1 (en) Bicyclic cyclohexylamines and their use as nmda receptor antagonists
DK0711283T3 (da) Tetrahydro-1H-benzazepinoner og hexahydroazepinoner som selektive cholecystokinin-B-receptorantagonister
CA2370834A1 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
DE69412073D1 (de) Xanthinderivate als adenosin-a1 rezeptor antagonisten
BR0007686A (pt) Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
LTIP1958A (en) New use of ropivacaine
SE9404438D0 (sv) New process
DE69631597D1 (de) Kombination aus einem beta rezeptorblocker und einem opioid
IL123536A0 (en) 5-HT3 Receptor antagonists for dyskinesia
WO2002007726A3 (en) Treatment of movement disorders